Creative Biolabs, a global Contract Research Organization, has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services. The platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support biotechnology companies and academic institutions in accelerating RNA therapeutics development.
Traditional ASO development often requires researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs' new service unifies the entire pipeline under one roof, addressing core hurdles such as high binding affinity, enzymatic degradation, and tissue-specific delivery.
The platform includes proprietary bioinformatic optimization using thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions and mitigate off-target risks. It offers advanced chemical modification and synthesis, including Gapmers and steric-blocking oligos, with capabilities ranging from milligram to multi-gram scales. Modifications such as PS backbones, PMO, and sugar modifications (2'-MOE, cEt) improve nuclease resistance and support in vivo stability.
Precision delivery and conjugation technologies solve cellular uptake barriers through custom targeted delivery, including GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations. Robust preclinical validation provides data-rich in vitro screening, such as mRNA knockdown via qPCR and cytotoxicity testing, as well as in vivo PK/PD profiling to support candidate selection.
According to the Chief Scientific Officer at Creative Biolabs, many therapeutic pipelines stall because high-affinity sequences fail under physiological conditions due to poor delivery or low stability. The one-stop platform eliminates these silos by matching customized chemical modifications with precise conjugation chemistries early in the design phase, potentially lowering required doses and improving safety profiles.
With a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, Creative Biolabs aims to provide the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development. More information can be found at Creative Biolabs Gene Therapy.
